Changes in Cardiac Autonomic Nervous System Following Atrial Fibrillation Ablation.
NCT ID: NCT03811639
Last Updated: 2021-02-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
126 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-01
Study Completion Date
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim. To compare changes in cardiac autonomic tone caused by radio-frequency versus cryoballoon ablation and to assess their value in predicting the outcome.
Study group. In this prospective randomized study 126 consecutive patients with paroxysmal AF undergoing first ablation of AF using radio-frequency (RF) or cryoballoon (CB) technique will be recruited. Patients will undergo several ECG and autonomic tests before and after the procedure. The follow-up will last one year.
Measurements:
1. Standard 12-lead ECG a day before and 1-2 days after the procedure will be performed. The SR and P wave duration as well as the difference (∆) in SR and P wave duration before and after ablation will be analyzed.
2. A 24-hour Holter ECG will be performed at baseline (1-2 days before ablation) and 7-day Holter ECG will be performed 3, 6 and 12 months after the procedure. Minimal, maximal and mean heart rate (HR) as well as HRV parameters will be analyzed. The differences (∆) in these variables between baseline and post-ablation Holter ECG recordings will be analyzed.
3. Autonomic parameters (HR, HRV parameters and baroreceptor reflex sensitivity as well as hemodynamic parameters (stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR)) will be also examined before and after orthostatic stress. This will be performed using tilt table test and non-invasive measurement of autonomic and hemodynamic parameters before and shortly after (1-3 days) the procedure.
4. Quality of life will be assessed using the AFSS scale and EHRA scale at baseline and 3, 6 and 12 months after ablation.
5. Follow-up will last 12 months. Efficacy of ablation will be assessed during outpatients visits and using 7-day Holter ECG recordings 3, 6 and 12 months after the procedure. The analyzed outcomes will include symptomatic recurrences of AF, hospitalizations due to AF, redo procedures i occurrence of asymptomatic AF on Holter ECG monitoring.
6. All the above listed parameters and ablation efficacy will be compared between the RF and CB groups.
Anticipated results.
1. Ablation significantly effects the parameters of cardiac autonomic control
2. These effects are more pronounced in the CB group compared with the RF group
3. Changes in autonomic indices have value in predicting ablation efficacy in both analyzed groups.
Study group. In this prospective randomized study 126 consecutive patients with paroxysmal AF undergoing first ablation of AF using radio-frequency (RF) or cryoballoon (CB) technique will be recruited. Patients will undergo several ECG and autonomic tests before and after the procedure. The follow-up will last one year.
Measurements:
1. Standard 12-lead ECG a day before and 1-2 days after the procedure will be performed. The SR and P wave duration as well as the difference (∆) in SR and P wave duration before and after ablation will be analyzed.
2. A 24-hour Holter ECG will be performed at baseline (1-2 days before ablation) and 7-day Holter ECG will be performed 3, 6 and 12 months after the procedure. Minimal, maximal and mean heart rate (HR) as well as HRV parameters will be analyzed. The differences (∆) in these variables between baseline and post-ablation Holter ECG recordings will be analyzed.
3. Autonomic parameters (HR, HRV parameters and baroreceptor reflex sensitivity as well as hemodynamic parameters (stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR)) will be also examined before and after orthostatic stress. This will be performed using tilt table test and non-invasive measurement of autonomic and hemodynamic parameters before and shortly after (1-3 days) the procedure.
4. Quality of life will be assessed using the AFSS scale and EHRA scale at baseline and 3, 6 and 12 months after ablation.
5. Follow-up will last 12 months. Efficacy of ablation will be assessed during outpatients visits and using 7-day Holter ECG recordings 3, 6 and 12 months after the procedure. The analyzed outcomes will include symptomatic recurrences of AF, hospitalizations due to AF, redo procedures i occurrence of asymptomatic AF on Holter ECG monitoring.
6. All the above listed parameters and ablation efficacy will be compared between the RF and CB groups.
Anticipated results.
1. Ablation significantly effects the parameters of cardiac autonomic control
2. These effects are more pronounced in the CB group compared with the RF group
3. Changes in autonomic indices have value in predicting ablation efficacy in both analyzed groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
NCT05410379
Atrial Fibrillation (AF)
COMPLETED
Effect of Cryoballoon and RF Ablation on Left Atrial Function
NCT02611869
Atrial Fibrillation
UNKNOWN
NA
Left Atrial Cryoablation Enhanced by Ganglionated Plexi Ablation in the Treatment of Atrial Fibrillation
NCT03239262
Mitral Valve Disease
Coronary Artery Disease
Tricuspid Valve Disease
+2 more
COMPLETED
NA
Study Comparing Pulmonary Vein Isolation With the Cryoballoon, Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF)
NCT01038115
Atrial Fibrillation
COMPLETED
PHASE4
Radiofrequency Ablation of Atrial Fibrillation Under Totally Thoracoscope
NCT00844584
Atrial Fibrillation
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ABLation-induced changes in cardiac Autonomic Nervous System in patients with Atrial Fibrillation: radiofrequency versus cryoballoon techniques (the ABLANSAF study).
Introduction. The primary goal of ablation for atrial fibrillation (AF) is pulmonary vein isolation (PVI). The second mechanism of action of ablation is modification of cardiac autonomic tone by ablation of atrial ganglionated plexi, mainly of their parasympathetic component. Data in literature concerning this topic is scares. A few studies showed that ablation-induced changes in heart rate variability (HRV) or sinus rate (SR) predict the outcome. However, these data are preliminary and have not yet been included into clinical practice. Moreover, whether these effects depend on the technique used - radio-frequency (RF) ablation or cryoballoon (CB) ablation, has not yet been examined.
Aim. To compare the changes in cardiac autonomic tone caused by RF versus CB ablation and to assess their value in predicting the outcome after the procedure.
Hypothesis. We hypothesised that both techniques cause significant changes in cardiac autonomic innervation, however, these changes are significantly more pronounced following CB rather than RF ablation.
Methods. Study group. In this prospective randomised study 126 consecutive patients with paroxysmal AF undergoing first ablation of AF using RF or CB technique will be recruited. Patients will undergo several ECG and autonomic tests before and after the procedure. The follow-up will last one year.
Ablation The RF and CB ablation will be performed using standard approach. A patient will be randomly selected to RF or CB ablation. The only parameter influencing randomisation will be the presence of the common trunk of the left PV (visualised by computed tomography or rotational angiography) which is regarded as relative contraindication to CB because of anatomical difficulties in the positioning of balloon. In such cases the decision as to the type of procedure will be left to the discretion of the operator.
The CB PVI will be conducted in standard manner. Briefly, after injection of local anesthetic, both femoral veins is punctured. One long sheath (8.5 F Swartz, St. Jude, Saint Paul, USA) to cross interatrial septum is inserted in the right femoral vein. Another two short sheaths were inserted in the left femoral vein for the intracardiac echocardiographic probe (8 or 10 Fr Acunav, Acuson, Siemens, Berlin) and diagnostic catheter introduced into the coronary sinus. After crossing the septum and introducing guidewire into the left superior pulmonary vein (LSPV), long sheath is replaced with steerable sheath (14 F., Flexcath, Medtronic, Minneapolis, USA) and CB (28 mm, second generation) is introduced into the left atrium. Next, the Achieve (20 mm diameter) mapping catheter, (Medtronic, Milwaukee, USA) is placed in the LSPV ostium, CB inflated and contrast injected to confirm proper occlusion of LSPV. When PVI is achieved during first freezing lasting 180 - 240 sec and confirmed by PV potentials (PVP) disappearance within 60 seconds by recordings from the Achieve catheter, no second cryoapplication is performed. In case of incomplete occlusion, persistence or very late disappearance of PVP, suboptimal temperatures achieved (less than -36C) or very short thawing time, CB is repositioned and another cryo-application is delivered. Next, CB-PVI of the left inferior pulmonary vein (LIPV), right superior pulmonary vein (RSPV) and right inferior pulmonary vein (RIPV) is performed. Pacing of the right phrenic nerve is performed during CB of the right veins to avoid phrenic nerve palsy.
The RF ablation is performed in a standard manner using 3-D electro-anatomical system CARTO-3 (Biosense Webster, USA) and Smarttouch ablation catheter. Two separate transseptal punctures are performed under intracardiac echocardiography guidance. After reconstruction of the left atrial geometry using merging of the computed tomography or rotational angiography image with the CARTO map, the point-by-point PVI of each vein is performed. The ablation index is used to ensure the quality of RF applications. The Lasso circular catheter (Biosense Webster, USA) is used to assess PVI and diagnostic catheter placed in the coronary sinus is used for pacing manoeuvres.
Measurements:
1. Standard 12-lead ECG a day before and 1-2 days after the procedure will be performed. The SR and P wave duration as well as the difference (∆) in SR and P wave duration before and after ablation will be analysed.
2. A 24-hour Holter ECG will be performed at baseline (1-2 days before ablation) and 7-day Holter ECG will be performed 3, 6 and 12 months after the procedure. Minimal, maximal and mean heart rate (HR) as well as time-domain HRV parameters (SDNN, SDANN, pNN50, rMSSD) and frequency-domain HRV indices (LF, HF, LF/HF) will be analysed. The differences (∆) in these variables between baseline and post-ablation Holter ECG recordings will be analysed.
3. Autonomic parameters (HR, frequency-domain HRV parameters and baro-reflex sensitivity (BRS) using sequential method) as well as hemodynamic parameters (stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR)) will be also examined before and after orthostatic stress. This will be performed using tilt table test (70 degrees) and non-invasive measurement of autonomic and hemodynamic parameters (cardiac impedance method) using the Task Force system, before (1-2 days) and shortly after (1-3 days) the procedure. The 5-min ECG recordings will be used to calculate the values of autonomic and haemodynamic parameters. Also ∆ of these parameters will be computed. The values measured before and after ablation, before and after tilt testing as well ∆ will be compared.
4. Quality of life will be assessed using the AFSS scale and EHRA scale at baseline and 3, 6 and 12 months after ablation.
5. Follow-up will last 12 months. Efficacy of ablation will be assessed during outpatients visits and using 7-day Holter ECG recordings 3, 6 and 12 months after the procedure. The analysed outcomes will include symptomatic recurrences of AF, hospitalisations due to AF, redo procedures i occurrence of asymptomatic AF on Holter ECG monitoring. Efficacy of the procedure will be assessed and defined as (1) complete efficacy - no symptoms attributed to AF and no AF on Holter ECG monitoring; (2) symptomatic efficacy - no symptoms attributed to AF but AF episodes \> 30 sec recorded on Holter ECG monitoring; (3) partial efficacy - recurrences of symptomatic AF, however, of lower intensity, defined as improvement of at least 1 degree in the EHRA scale and improvement in the AFSS scale; and (4) no effects - no change in symptoms compared with the pre-ablation periods.
6. All the above listed parameters and ablation efficacy will be compared between the RF and CB groups.
Statistical analysis. The results will be presented as mean±SD (normally distributed variables) or median values (not normally distributed variables). The changes between baseline and parameters obtained after ablation as well as before and after tilt testing will be performed using paired two-tailed Student t-test, Mann-Whitney or ANOVA tests where appropriate. The results obtained in the RF versus CB groups will be compared using unpaired Student t-test. The predictive value of examined parameters in identifying responders to ablation will be assessed using the ROC curves and by computing sensitivity, specificity, positive and negative predictive value. Multivariate analysis will be performed to identify parameters independently associated with ablation efficacy. A p value \< 0.05 will be considered significant.
The estimated number of patients sufficient to detect significant difference between the RF and CB groups is 126 based on the assumption that ablation-induced changes in cardiac autonomic parameters will differ between the RF and CB groups by 20% (alfa error = 0.05 and beta error = 0.2) Anticipated results.
1. Ablation significantly effects the parameters of cardiac autonomic control
2. These effects are more pronounced in the CB group compared with the RF group
3. Changes in autonomic indices have value in predicting ablation efficacy in both analysed groups.
Introduction. The primary goal of ablation for atrial fibrillation (AF) is pulmonary vein isolation (PVI). The second mechanism of action of ablation is modification of cardiac autonomic tone by ablation of atrial ganglionated plexi, mainly of their parasympathetic component. Data in literature concerning this topic is scares. A few studies showed that ablation-induced changes in heart rate variability (HRV) or sinus rate (SR) predict the outcome. However, these data are preliminary and have not yet been included into clinical practice. Moreover, whether these effects depend on the technique used - radio-frequency (RF) ablation or cryoballoon (CB) ablation, has not yet been examined.
Aim. To compare the changes in cardiac autonomic tone caused by RF versus CB ablation and to assess their value in predicting the outcome after the procedure.
Hypothesis. We hypothesised that both techniques cause significant changes in cardiac autonomic innervation, however, these changes are significantly more pronounced following CB rather than RF ablation.
Methods. Study group. In this prospective randomised study 126 consecutive patients with paroxysmal AF undergoing first ablation of AF using RF or CB technique will be recruited. Patients will undergo several ECG and autonomic tests before and after the procedure. The follow-up will last one year.
Ablation The RF and CB ablation will be performed using standard approach. A patient will be randomly selected to RF or CB ablation. The only parameter influencing randomisation will be the presence of the common trunk of the left PV (visualised by computed tomography or rotational angiography) which is regarded as relative contraindication to CB because of anatomical difficulties in the positioning of balloon. In such cases the decision as to the type of procedure will be left to the discretion of the operator.
The CB PVI will be conducted in standard manner. Briefly, after injection of local anesthetic, both femoral veins is punctured. One long sheath (8.5 F Swartz, St. Jude, Saint Paul, USA) to cross interatrial septum is inserted in the right femoral vein. Another two short sheaths were inserted in the left femoral vein for the intracardiac echocardiographic probe (8 or 10 Fr Acunav, Acuson, Siemens, Berlin) and diagnostic catheter introduced into the coronary sinus. After crossing the septum and introducing guidewire into the left superior pulmonary vein (LSPV), long sheath is replaced with steerable sheath (14 F., Flexcath, Medtronic, Minneapolis, USA) and CB (28 mm, second generation) is introduced into the left atrium. Next, the Achieve (20 mm diameter) mapping catheter, (Medtronic, Milwaukee, USA) is placed in the LSPV ostium, CB inflated and contrast injected to confirm proper occlusion of LSPV. When PVI is achieved during first freezing lasting 180 - 240 sec and confirmed by PV potentials (PVP) disappearance within 60 seconds by recordings from the Achieve catheter, no second cryoapplication is performed. In case of incomplete occlusion, persistence or very late disappearance of PVP, suboptimal temperatures achieved (less than -36C) or very short thawing time, CB is repositioned and another cryo-application is delivered. Next, CB-PVI of the left inferior pulmonary vein (LIPV), right superior pulmonary vein (RSPV) and right inferior pulmonary vein (RIPV) is performed. Pacing of the right phrenic nerve is performed during CB of the right veins to avoid phrenic nerve palsy.
The RF ablation is performed in a standard manner using 3-D electro-anatomical system CARTO-3 (Biosense Webster, USA) and Smarttouch ablation catheter. Two separate transseptal punctures are performed under intracardiac echocardiography guidance. After reconstruction of the left atrial geometry using merging of the computed tomography or rotational angiography image with the CARTO map, the point-by-point PVI of each vein is performed. The ablation index is used to ensure the quality of RF applications. The Lasso circular catheter (Biosense Webster, USA) is used to assess PVI and diagnostic catheter placed in the coronary sinus is used for pacing manoeuvres.
Measurements:
1. Standard 12-lead ECG a day before and 1-2 days after the procedure will be performed. The SR and P wave duration as well as the difference (∆) in SR and P wave duration before and after ablation will be analysed.
2. A 24-hour Holter ECG will be performed at baseline (1-2 days before ablation) and 7-day Holter ECG will be performed 3, 6 and 12 months after the procedure. Minimal, maximal and mean heart rate (HR) as well as time-domain HRV parameters (SDNN, SDANN, pNN50, rMSSD) and frequency-domain HRV indices (LF, HF, LF/HF) will be analysed. The differences (∆) in these variables between baseline and post-ablation Holter ECG recordings will be analysed.
3. Autonomic parameters (HR, frequency-domain HRV parameters and baro-reflex sensitivity (BRS) using sequential method) as well as hemodynamic parameters (stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR)) will be also examined before and after orthostatic stress. This will be performed using tilt table test (70 degrees) and non-invasive measurement of autonomic and hemodynamic parameters (cardiac impedance method) using the Task Force system, before (1-2 days) and shortly after (1-3 days) the procedure. The 5-min ECG recordings will be used to calculate the values of autonomic and haemodynamic parameters. Also ∆ of these parameters will be computed. The values measured before and after ablation, before and after tilt testing as well ∆ will be compared.
4. Quality of life will be assessed using the AFSS scale and EHRA scale at baseline and 3, 6 and 12 months after ablation.
5. Follow-up will last 12 months. Efficacy of ablation will be assessed during outpatients visits and using 7-day Holter ECG recordings 3, 6 and 12 months after the procedure. The analysed outcomes will include symptomatic recurrences of AF, hospitalisations due to AF, redo procedures i occurrence of asymptomatic AF on Holter ECG monitoring. Efficacy of the procedure will be assessed and defined as (1) complete efficacy - no symptoms attributed to AF and no AF on Holter ECG monitoring; (2) symptomatic efficacy - no symptoms attributed to AF but AF episodes \> 30 sec recorded on Holter ECG monitoring; (3) partial efficacy - recurrences of symptomatic AF, however, of lower intensity, defined as improvement of at least 1 degree in the EHRA scale and improvement in the AFSS scale; and (4) no effects - no change in symptoms compared with the pre-ablation periods.
6. All the above listed parameters and ablation efficacy will be compared between the RF and CB groups.
Statistical analysis. The results will be presented as mean±SD (normally distributed variables) or median values (not normally distributed variables). The changes between baseline and parameters obtained after ablation as well as before and after tilt testing will be performed using paired two-tailed Student t-test, Mann-Whitney or ANOVA tests where appropriate. The results obtained in the RF versus CB groups will be compared using unpaired Student t-test. The predictive value of examined parameters in identifying responders to ablation will be assessed using the ROC curves and by computing sensitivity, specificity, positive and negative predictive value. Multivariate analysis will be performed to identify parameters independently associated with ablation efficacy. A p value \< 0.05 will be considered significant.
The estimated number of patients sufficient to detect significant difference between the RF and CB groups is 126 based on the assumption that ablation-induced changes in cardiac autonomic parameters will differ between the RF and CB groups by 20% (alfa error = 0.05 and beta error = 0.2) Anticipated results.
1. Ablation significantly effects the parameters of cardiac autonomic control
2. These effects are more pronounced in the CB group compared with the RF group
3. Changes in autonomic indices have value in predicting ablation efficacy in both analysed groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atrial Fibrillation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Comparison of changes in autonomic heart regulation caused by radio-frequency ablation and cryoballoon ablation
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RF ablation
Patients treated with point-by-point radio-frequency ablation
Group Type
ACTIVE_COMPARATOR
Radio-frequency ablation
Intervention Type
PROCEDURE
Ablation for atrial fibrillation
Cryoballoon ablation
Patients treated with cryoballoon ablation
Group Type
EXPERIMENTAL
Cryoballoon ablation
Intervention Type
PROCEDURE
Ablation for atrial fibrillation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radio-frequency ablation
Ablation for atrial fibrillation
Intervention Type
PROCEDURE
Cryoballoon ablation
Ablation for atrial fibrillation
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Paroxysmal AF
* First AF ablation
* Sinus rhythm before and after the procedure at the time of ECG and tilt table testing.
* No change in medication affecting cardiac autonomic nervous system before and after ablation.
* Obtained written informed consent to participate in the study.
* First AF ablation
* Sinus rhythm before and after the procedure at the time of ECG and tilt table testing.
* No change in medication affecting cardiac autonomic nervous system before and after ablation.
* Obtained written informed consent to participate in the study.
Exclusion Criteria
* Any of inclusion criterion not met
* Pacing system implanted
* Additional ablation to PVI like cavo-tricuspid isthmus ablation or linear lesions in the left atrium.
* Pacing system implanted
* Additional ablation to PVI like cavo-tricuspid isthmus ablation or linear lesions in the left atrium.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre of Postgraduate Medical Education
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Piotr Kulakowski
Professor, head of Electrophysiology Department
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Piotr Kulakowski, MD
Role: STUDY_CHAIR
Postgraduate Medical School, Grochowski Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Postgraduate Medical School, Grochowski Hospital
Warsaw, , Poland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Poland
References
Explore related publications, articles, or registry entries linked to this study.
Hsieh MH, Chiou CW, Wen ZC, Wu CH, Tai CT, Tsai CF, Ding YA, Chang MS, Chen SA. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation. 1999 Nov 30;100(22):2237-43. doi: 10.1161/01.cir.100.22.2237.
Reference Type
BACKGROUND
Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, Lang C, Tomita T, Mesas C, Mastella E, Alfieri O. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109(3):327-34. doi: 10.1161/01.CIR.0000112641.16340.C7. Epub 2004 Jan 5.
Reference Type
RESULT
Yamada T, Yoshida N, Murakami Y, Okada T, Yoshida Y, Muto M, Inden Y, Murohara T. Vagal modification can be a valid predictor of late recurrence of paroxysmal atrial fibrillation independent of the pulmonary vein isolation technique. Circ J. 2009 Sep;73(9):1606-11. doi: 10.1253/circj.cj-09-0158. Epub 2009 Jul 17.
Reference Type
RESULT
Yamada T, Yoshida N, Murakami Y, Okada T, Yoshida Y, Muto M, Inden Y, Murohara T. The difference in autonomic denervation and its effect on atrial fibrillation recurrence between the standard segmental and circumferential pulmonary vein isolation techniques. Europace. 2009 Dec;11(12):1612-9. doi: 10.1093/europace/eup330. Epub 2009 Oct 29.
Reference Type
RESULT
Yamaguchi Y, Kumagai K, Nakashima H, Saku K. Long-term effects of box isolation on sympathovagal balance in atrial fibrillation. Circ J. 2010 Jun;74(6):1096-103. doi: 10.1253/circj.cj-09-0899. Epub 2010 May 8.
Reference Type
RESULT
Oswald H, Klein G, Koenig T, Luesebrink U, Duncker D, Gardiwal A. Cryoballoon pulmonary vein isolation temporarily modulates the intrinsic cardiac autonomic nervous system. J Interv Card Electrophysiol. 2010 Oct;29(1):57-62. doi: 10.1007/s10840-010-9491-7. Epub 2010 Jun 16.
Reference Type
RESULT
Lim PB, Malcolme-Lawes LC, Stuber T, Koa-Wing M, Wright IJ, Tillin T, Sutton R, Davies DW, Peters NS, Francis DP, Kanagaratnam P. Feasibility of multiple short, 40-s, intra-procedural ECG recordings to detect immediate changes in heart rate variability during catheter ablation for arrhythmias. J Interv Card Electrophysiol. 2011 Nov;32(2):163-71. doi: 10.1007/s10840-011-9580-2. Epub 2011 Jun 7.
Reference Type
RESULT
Wang K, Chang D, Chu Z, Yang Y, Gao L, Zhang S, Xia Y, Dong Y, Yin X, Cong P, Jia J. Denervation as a common mechanism underlying different pulmonary vein isolation strategies for paroxysmal atrial fibrillation: evidenced by heart rate variability after ablation. ScientificWorldJournal. 2013 Aug 24;2013:569564. doi: 10.1155/2013/569564. eCollection 2013.
Reference Type
RESULT
Seaborn GE, Todd K, Michael KA, Baranchuk A, Abdollah H, Simpson CS, Akl SG, Redfearn DP. Heart rate variability and procedural outcome in catheter ablation for atrial fibrillation. Ann Noninvasive Electrocardiol. 2014 Jan;19(1):23-33. doi: 10.1111/anec.12098. Epub 2013 Sep 24.
Reference Type
RESULT
Kang KW, Kim TH, Park J, Uhm JS, Joung B, Hwang C, Lee MH, Pak HN. Long-term changes in heart rate variability after radiofrequency catheter ablation for atrial fibrillation: 1-year follow-up study with irrigation tip catheter. J Cardiovasc Electrophysiol. 2014 Jul;25(7):693-700. doi: 10.1111/jce.12398. Epub 2014 Mar 28.
Reference Type
RESULT
Mori H, Kato R, Ikeda Y, Goto K, Tanaka S, Asano S, Shiki Y, Nagase T, Iwanaga S, Nishimura S, Muramatsu T, Matsumoto K. Analysis of the heart rate variability during cryoballoon ablation of atrial fibrillation. Europace. 2018 Aug 1;20(8):1259-1267. doi: 10.1093/europace/eux225.
Reference Type
RESULT
Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN. Prognosis of high sinus heart rate after catheter ablation for atrial fibrillation. Europace. 2017 Jul 1;19(7):1132-1139. doi: 10.1093/europace/euw142.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
65/PB/2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Atrial Fibrillation Ablation and Autonomic Modulation Via Thorascopic Surgery
NCT01091389
COMPLETED
PHASE4
Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months
NCT00259623
COMPLETED
NA
Effect of the Autonomic Nervous System on the Outcomes of PULSEd Field Ablation to Treat Atrial Fibrillation
NCT06351553
NOT_YET_RECRUITING
NA
Ablation of Atrial Fibrillation in Heart Failure Patients
NCT03062241
UNKNOWN
NA
Real Zero Fluoroscopy Catheter Ablation.
NCT03458273
UNKNOWN
Atrial Fibrillation Registry 2017
NCT05023590
UNKNOWN
NA
Ablation of Anisochronous Zones vs Spatio-temporal Dispersal Zones With Antral Electrical Isolation During Radiofrequency Treatment of Paroxysmal or Persistent Atrial Fibrillation
NCT03564951
COMPLETED
NA
Zero-fluoroscopic Cryoballoon Ablation
NCT05711589
COMPLETED
NA
CAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories
NCT05364866
UNKNOWN
Atrial Fibrillation Ablation: Radiofrequency or Cryoablation?
NCT03774550
COMPLETED
Heart Rate Variability After Ablation
NCT06276296
UNKNOWN
High Power vs Standard Power RF Ablation of Atrial Fibrillation in Conscious Patients
NCT04250181
COMPLETED
Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation
NCT03348436
COMPLETED
NA
Analysis of Endocavitary Electrical Signal and Surface Electrocardiogram to Predict Ablation Outcome in Persistent Atrial Fibrillation
NCT03937089
COMPLETED
Surgical Ablation for Atrial Fibrillation
NCT04398979
COMPLETED
Identification of Risk Factors for Atrial Fibrillation After Ablation of an Atrial Flutter by Radiofrequency of the Cavotricuspid Isthmus.
NCT03919097
COMPLETED
Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart
NCT06505798
RECRUITING
NA
Cryoballoon Ablation of Pulmonary Veins After Failed RF Ablation in Patients With Paroxysmal AF
NCT01611701
COMPLETED
PHASE3
REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation With Active Esophageal COOLing: A Sub-Study of the REAL AF Registry
NCT06354777
ACTIVE_NOT_RECRUITING
Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging
NCT05432024
RECRUITING
Assess Differences in Pain Following Cryo and Radiofrequency Atrial Fibrillation Ablation
NCT03148392
UNKNOWN
Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
NCT04942834
RECRUITING
NA
A New Approach for Catheter Ablation of Atrial Fibrillation
NCT05989321
COMPLETED
Prognostic Factors for Ablation of Atrial Fibrillation
NCT05716581
NOT_YET_RECRUITING